PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
AboutPricing
Drug ReportsTiagabine
Tiagabine
Gabitril, Tiagabine (tiagabine) is a small molecule pharmaceutical. Tiagabine was first approved as Gabitril on 1997-09-30. It is used to treat bipolar disorder, epilepsy, and partial epilepsies in the USA. The pharmaceutical is active against sodium- and chloride-dependent GABA transporter 1.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
nervous system diseasesD009422
mental disordersD001523
Trade Name
FDA
EMA
Gabitril, Tiagabine (discontinued: Gabitril, Tiagabine)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Tiagabine hydrochloride
Tradename
Company
Number
Date
Products
GABITRILCephalonN-020646 RX1997-09-30
4 products, RLD
Show 1 discontinued
Labels
FDA
EMA
Brand Name
Status
Last Update
gabitrilNew Drug Application2016-08-06
tiagabine hydrochlorideANDA2023-12-30
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
epilepsyEFO_0000474D004827G40.9
partial epilepsiesEFO_0004263D004828—
bipolar disorderEFO_0000289D001714F30.9
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
N: Nervous system drugs
— N03: Antiepileptics
— N03A: Antiepileptics
— N03AG: Fatty acid derivatives, antiepileptics
— N03AG06: Tiagabine
HCPCS
No data
Clinical
Clinical Trials
21 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Anxiety disordersD001008EFO_0006788F41.1——52—7
EpilepsyD004827EFO_0000474G40.9———325
Partial epilepsiesD004828EFO_0004263————2—2
Intellectual disabilityD008607EFO_0003847F73———1—1
Drug resistant epilepsyD000069279—————1—1
Social phobiaD000072861EFO_1001917F40.1———1—1
Physiological sexual dysfunctionD012735—————1—1
AnxietyD001007EFO_0005230F41.1———1—1
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
SchizophreniaD012559EFO_0000692F20——1——1
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Cocaine-related disordersD019970—F14—4———4
Central nervous system neoplasmsD016543——12———2
Nervous system neoplasmsD009423——12———2
Opioid-related disordersD009293EFO_0005611F11—1———1
Obstructive sleep apneaD020181EFO_0003918G47.33—1———1
Sleep apnea syndromesD012891HP_0010535G47.3—1———1
ApneaD001049HP_0002104R06.81—1———1
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
AlcoholismD000437EFO_0003829F10.11————1
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Financial stressD000086522——————11
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameTiagabine
INNtiagabine
Description
Tiagabine is a piperidinemonocarboxylic acid that is (R)-nipecotic acid in which the hydrogen attached to the nitrogen has been replaced by a 1,1-bis(3-methyl-2-thienyl)but-1-en-4-yl group. A GABA reuptake inhibitor, it is used (generally as the hydrochloride salt) for the treatment of epilepsy. It has a role as a GABA reuptake inhibitor and an anticonvulsant. It is a piperidinemonocarboxylic acid, a beta-amino acid, a member of thiophenes and a tertiary amino compound. It is functionally related to a (R)-nipecotic acid. It is a conjugate base of a tiagabine(1+).
Classification
Small molecule
Drug classgabamimetics
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)
Cc1ccsc1C(=CCCN1CCC[C@@H](C(=O)O)C1)c1sccc1C
Identifiers
PDB—
CAS-ID115103-54-3
RxCUI—
ChEMBL IDCHEMBL1027
ChEBI ID9586
PubChem CID60648
DrugBankDB00906
UNII IDZ80I64HMNP (ChemIDplus, GSRS)
Target
Agency Approved
SLC6A1
SLC6A1
Organism
Homo sapiens
Gene name
SLC6A1
Gene synonyms
GABATR, GABT1, GAT1
NCBI Gene ID
6529
Protein name
sodium- and chloride-dependent GABA transporter 1
Protein synonyms
GABA transporter 1, solute carrier family 6 (neurotransmitter transporter), member 1, solute carrier family 6 (neurotransmitter transporter, GABA), member 1, Solute carrier family 6 member 1
Uniprot ID
Q8N4K8
Mouse ortholog
Slc6a1 (232333)
sodium- and chloride-dependent GABA transporter 1 (P31648)
Alternate
No data
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
Gabitril – Cephalon
Plot placeholder
Mock data
Subscribe for the real data
Plot placeholder
Mock data
Subscribe for the real data
Tabular view
Estimated US medical usage
Tiagabine
Total medical expenditures per year (USD, in millions)
Plot placeholder
Mock data
Subscribe for the real data
Number of persons purchased
Plot placeholder
Mock data
Subscribe for the real data
Number of purchases
Plot placeholder
Mock data
Subscribe for the real data
Refill frequency
Plot placeholder
Mock data
Subscribe for the real data
Price per prescription (USD)
Plot placeholder
Mock data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 2,375 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
844 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use